AnGes Inc (4563) - Financial and Strategic SWOT Analysis Review

AnGes Inc (4563) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description - A detailed description of the company’s operations and business divisions.
• Corporate strategy - Analyst’s summarization of the company’s business strategy.
• SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history - Progression of key events associated with the company.
• Major products and services - A list of major products, services and brands of the company.
• Key competitors - A list of key competitors to the company.
• Key employees - A list of the key executives of the company.
• Executive biographies - A brief summary of the executives’ employment history.
• Key operational heads - A list of personnel heading key departments/functions.
• Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

AnGes Inc (AnGes) is a biopharmaceutical company that discovers and develops gene and nucleotide-based drugs and reagents for use in the functional analysis of genetic medications. The company specializes in the research and development (R&D) and practical application of genetic medicines. AnGes' lead product, Zokinvy, is used for the treatment of HGPS/PDPL. It has major projects under development, such as hepatocyte growth factor (HGF) gene therapy products for Chronic arterial occlusive disease, NF-?B decoy oligonucleotide for Chronic discogenic lumbar back pain, and the development of hypertension and COVID-19 DNA vaccines. The company also focuses on the development of rare diseases and has n-licensed drugs for Mucopolysaccharidosis Type VI and Hutchinson-Gilford Progeria Syndrome. It has operations in the US and Japan. AnGes is headquartered in Ibaraki, Osaka, Japan.

AnGes Inc Key Recent Developments

• Sep 11, 2025: Results of Clinical Trials of HGF Gene Therapy Products in the US Announced at the 9th Cell & Gene Therapy World Asia 2025
• Aug 26, 2025: Anges Clinical Research Laboratory Announces the Start of Contract Testing for Biomarkers for Mucopolysaccharidosis
• Feb 14, 2025: AnGes : Notice of Recording of Non-Operating Income, Non-operating Expenses, Extraordinary Income, Extraordinary Loss, Income Tax Adjustment and Difference between Consolidated Earnings Forecast and Actual Results for the Fiscal Year Ended December 31, 2024

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company